NewAmsterdam Pharma (NAMS) Non-cash Items (2023 - 2026)

NewAmsterdam Pharma has disclosed Non-cash Items across 4 years of filings, most recently posting $327.6 million for Q1 2026.

• Non-cash Items for Q1 2026 came in at $327.6 million, up 78.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $327.6 million (up 78.26% YoY), and the FY2025 annual result was $10.1 million, down 96.62% from the prior year.
• Non-cash Items came in at $327.6 million for Q1 2026 at NewAmsterdam Pharma, up from $10.1 million in the prior quarter.
• In the past five years, Non-cash Items ranged from a high of $327.6 million in Q1 2026 to a low of $6.1 million in Q1 2024.
• The 4-year median for Non-cash Items is $30.4 million (2023), against an average of $104.9 million.
• Peak annual rise in Non-cash Items reached 2895.97% in 2025, while the deepest fall reached 96.62% in 2025.
• NewAmsterdam Pharma's Non-cash Items stood at $50.8 million in 2023, then jumped by 486.62% to $298.0 million in 2024, then tumbled by 96.62% to $10.1 million in 2025, then jumped by 3148.71% to $327.6 million in 2026.
• The last three Non-cash Items figures came in at $327.6 million (Q1 2026), $10.1 million (Q4 2025), and $10.1 million (Q3 2025), per Business Quant data.